Literature DB >> 16964317

Physician patterns of metabolic screening for patients taking atypical antipsychotics: a retrospective database study.

Charles Motsinger1, Michael Slack, Melanie Weaver, Morgan Reed.   

Abstract

OBJECTIVE: The aim of this retrospective database study was to determine rates of screening for metabolic side effects by physician specialty in community hospital patients prescribed atypical antipsychotics.
METHOD: A pharmacy database review identified patients who were prescribed atypical antipsychotics over a 6-month period from July 1, 2004, to December 31, 2004. This list of patients was then cross-referenced with the laboratory database to determine if screening laboratory tests for metabolic abnormalities had been ordered.
RESULTS: 13% of patients prescribed atypical antipsychotics had fasting blood glucose levels measured during the study period. 30% of patients prescribed atypical antipsychotics also had lipid panels measured during the study period. Screening rates varied by specialty of physician. Physicians trained in combined family practice and psychiatry had the highest rate of screening, followed by other nonpsychiatric specialties. Psychiatrists had the lowest rate of screening.
CONCLUSIONS: The rate of screening for metabolic side effects of atypical antipsychotics in this community hospital setting was low.

Entities:  

Year:  2006        PMID: 16964317      PMCID: PMC1557474          DOI: 10.4088/pcc.v08n0405

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  9 in total

1.  Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  R S Doody; J C Stevens; C Beck; R M Dubinsky; J A Kaye; L Gwyther; R C Mohs; L J Thal; P J Whitehouse; S T DeKosky; J L Cummings
Journal:  Neurology       Date:  2001-05-08       Impact factor: 9.910

Review 2.  Consensus development conference on antipsychotic drugs and obesity and diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

Review 3.  Modern antipsychotic drugs: a critical overview.

Authors:  David M Gardner; Ross J Baldessarini; Paul Waraich
Journal:  CMAJ       Date:  2005-06-21       Impact factor: 8.262

Review 4.  Understanding the new and evolving profile of adverse drug effects in schizophrenia.

Authors:  Donna A Wirshing; Joseph M Pierre; Stephen M Erhart; Jennifer A Boyd
Journal:  Psychiatr Clin North Am       Date:  2003-03

Review 5.  Metabolic issues and cardiovascular disease in patients with psychiatric disorders.

Authors:  Daniel E Casey
Journal:  Am J Med       Date:  2005-04       Impact factor: 4.965

6.  Treatment of borderline personality disorder with risperidone.

Authors:  Paola Rocca; Livio Marchiaro; Elena Cocuzza; Filippo Bogetto
Journal:  J Clin Psychiatry       Date:  2002-03       Impact factor: 4.384

7.  Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.

Authors:  Alexander Bystritsky; Deborah L Ackerman; Richard M Rosen; Tanya Vapnik; Eda Gorbis; Karron M Maidment; Sanjaya Saxena
Journal:  J Clin Psychiatry       Date:  2004-04       Impact factor: 4.384

8.  Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study.

Authors:  Murray B Stein; Neal A Kline; Jeffrey L Matloff
Journal:  Am J Psychiatry       Date:  2002-10       Impact factor: 18.112

Review 9.  Clinical use of quetiapine in disease states other than schizophrenia.

Authors:  S Charles Schulz
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

  9 in total
  6 in total

1.  The appropriateness of routine medication treatment for schizophrenia.

Authors:  Alexander S Young; Noosha Niv; Amy N Cohen; Christopher Kessler; Kirk McNagny
Journal:  Schizophr Bull       Date:  2008-11-07       Impact factor: 9.306

2.  Side effects of atypical antipsychotics: a brief overview.

Authors:  Alp Uçok; Wolfgang Gaebel
Journal:  World Psychiatry       Date:  2008-02       Impact factor: 49.548

3.  Antipsychotic Cardiometabolic Side Effect Monitoring in a State Community Mental Health System.

Authors:  Robert O Cotes; Alex de Nesnera; Michael Kelly; Karen Orsini; Haiyi Xie; Greg McHugo; Stephen Bartels; Mary F Brunette
Journal:  Community Ment Health J       Date:  2015-02-03

4.  Does a Physician's Attitude toward a Patient with Mental Illness Affect Clinical Management of Diabetes? Results from a Mixed-Method Study.

Authors:  Lisa C Welch; Heather J Litman; Christina P C Borba; Brenda Vincenzi; David C Henderson
Journal:  Health Serv Res       Date:  2014-12-09       Impact factor: 3.402

5.  A UK audit of screening for the metabolic side effects of antipsychotics in community patients.

Authors:  Thomas R E Barnes; Carol Paton; Mary-Rose Cavanagh; Elizabeth Hancock; David M Taylor
Journal:  Schizophr Bull       Date:  2007-05-04       Impact factor: 9.306

6.  Testing the Use of Data Drawn from the Electronic Health Record to Compare Quality.

Authors:  Kathleen E Walsh; Hanieh Razzaghi; David M Hartley; Levon Utidjian; Shannon Alford; Rahul A Darwar; Elizabeth Shenkman; Susannah Jonas; Mary Goodick; Jonathan Finkelstein; Al Ozonoff; L Vandy Black; Michael Shapiro; Kathryn Shaw; Jennifer McCafferty-Fernandez; Keith Marsolo; Amy Kelly; Lloyd N Werk; Jordan Smallwood; Charles Bailey
Journal:  Pediatr Qual Saf       Date:  2021-07-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.